Diabetes

AI Screening for Diabetic Retinopathy Is Cost-Effective for At-Risk Children

September 03, 2020

At recommended adherence rates, automatic AI screening technology for diabetic retinopathy is a preferred strategy over conventional eye care professional screening.

Researchers Identify More Risk Factors for Chronic Kidney Disease Progression

September 02, 2020

For patients without diabetes, low serum bicarbonate and higher high sensitivity troponin T, NTproBNP, and urine NGAL were linked to a higher risk of the composite outcome.

Empagliflozin Improves CV Outcomes in Patients with Obstructive Sleep Apnea

September 01, 2020

Investigators report on a post-hoc analysis of the EMPA-REG OUTCOME trial that assesses the efficacy of the SGLT-2 inhibitor in patients with obstructive sleep apnea.

New Lifetime Risk Equation More Accurately Predicts CV Risk and Treatment Benefits

September 01, 2020

The new equation model has shown to be more accurate than the Framingham Lifetime Risk equation and Pooled Cohort Equation.

BMI Strongly Predicts Individual Risk for Diabetes

August 31, 2020

New data shows that high BMI individuals who were in the lowest polygenic score quintile had a 5-fold greater risk of diabetes than those with low BMI and a high polygenic score.

SGLT2 Inhibitors Emerge As Treatment Options for Heart Failure Patients

August 30, 2020

Dapagliflozin and empagliflozin are shown to minimize CV events in patients with heart failure and a reduced ejection fraction.

Closed-Loop Glucose Controller Safe, Effective for Adults with Type 1 Diabetes

August 28, 2020

The system maintains tight glucose control and reduces the risk of hypoglycemia.

Investigators Link an SNP to Diabetic Retinopathy Protection

August 14, 2020

A single nucleotide polymorphism is associated with severe and proliferative retinopathy risk reduction by 42% and 63%, respectively.

Evolocumab Reduces Cardiovascular Risk in Metabolic Syndrome Patients

August 12, 2020

Treatment with the PCSK9 Inhibitor did not increase risk of safety events, including new-onset diabetes.

DDP-4 Inhibitors Increase Risk of Bullous Pemphigoid

August 05, 2020

Older, white patients and those who use linagliptin are at a higher risk of bullous pemphigoid.